Renal Sympathetic Denervation for Treatment of Drug-Resistant Hypertension One-Year Results From the Symplicity HTN-2 Randomized, Controlled Trial

被引:339
|
作者
Esler, Murray D. [1 ]
Krum, Henry [2 ]
Schlaich, Markus [1 ]
Schmieder, Roland E. [3 ]
Boehm, Michael [4 ]
Sobotka, Paul A. [5 ]
机构
[1] Baker IDI Heart & Diabet Inst, Melbourne, Vic 3004, Australia
[2] Monash Univ, Monash Ctr Cardiovasc Res & Educ Therapeut, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3004, Australia
[3] Univ Hosp, Clin Res Competence Ctr Hypertens & Vasc Med, Dept Hypertens & Nephrol, Erlangen, Germany
[4] Univ Klinikum Saarlandes, Homburg, Germany
[5] Ohio State Univ, Columbus, OH 43210 USA
关键词
catheter ablation; hypertension; nervous system; sympathetic; renal denervation; sympathetic nervous system; BLOOD-PRESSURE; MODULATION;
D O I
10.1161/CIRCULATIONAHA.112.130880
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Renal sympathetic nerve activation contributes to the pathogenesis of hypertension. Symplicity HTN-2, a multicenter, randomized trial, demonstrated that catheter-based renal denervation produced significant blood pressure lowering in treatment-resistant patients at 6 months after the procedure compared with control, medication-only patients. Longer-term follow-up, including 6-month crossover results, is now presented. Methods and Results-Eligible patients were on >= 3 antihypertensive drugs and had a baseline systolic blood pressure >= 160 mm Hg (>= 150 mm Hg for type 2 diabetics). After the 6-month primary end point was met, renal denervation in control patients was permitted. One-year results on patients randomized to immediate renal denervation (n = 47) and 6-month postprocedure results for crossover patients are presented. At 12 months after the procedure, the mean fall in office systolic blood pressure in the initial renal denervation group (-28.1 mm Hg; 95% confidence interval, -35.4 to -20.7; P < 0.001) was similar to the 6-month fall (-31.7 mm Hg; 95% confidence interval, -38.3 to -25.0; P=0.16 versus 6-month change). The mean systolic blood pressure of the crossover group 6 months after the procedure was significantly lowered (from 190.0 +/- 19.6 to 166.3 +/- 24.7 mm Hg; change, -23.7 +/- 27.5; P < 0.001). In the crossover group, there was 1 renal artery dissection during guide catheter insertion, before denervation, corrected by renal artery stenting, and 1 hypotensive episode, which resolved with medication adjustment. Conclusions-Control patients who crossed over to renal denervation with the Symplicity system had a significant drop in blood pressure similar to that observed in patients receiving immediate denervation. Renal denervation provides safe and sustained reduction of blood pressure to 1 year. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00888433. (Circulation. 2012;126:2976-2982.)
引用
收藏
页码:2976 / 2982
页数:7
相关论文
共 50 条
  • [2] RENAL SYMPATHETIC DENERVATION FOR TREATMENT OF RESISTANT HYPERTENSION: ONE YEAR RESULTS FROM THE SYMPLICITY HTN-2 RANDOMIZED CONTROLLED TRIAL
    Esler, Murray D.
    Krum, Henry
    Schlaich, Markus
    Schmieder, Roland
    Bohm, Michael
    Sobotka, Paul
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E1705 - E1705
  • [3] RENAL SYMPATHETIC DENERVATION FOR TREATMENT OF RESISTANT HYPERTENSION: TWO-YEAR UPDATE FROM THE SYMPLICITY HTN-2 RANDOMIZED CONTROLLED TRIAL
    Esler, Murray
    Krum, Henry
    Schmieder, Roland
    Bohm, Michael
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (10) : E1386 - E1386
  • [4] Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
    Esler, Murray D.
    Krum, Henry
    Sobotka, Paul A.
    Schlaich, Markus P.
    Schmieder, Roland E.
    Boehm, Michael
    Mahfoud, Felix
    Sievert, Horst
    Wunderlich, Nina
    Rump, Lars Christian
    Vonend, Oliver
    Uder, Michael
    Lobo, Mel
    Caulfield, Mark
    Erglis, Andrejs
    Azizi, Michel
    Sapoval, Marc
    Thambar, Suku
    Persu, Alexandre
    Renkin, Jean
    Schunkert, Heribert
    Weil, Joachim
    Hoppe, Uta C.
    Walton, Tony
    Scheinert, Dierk
    Binder, Thomas
    Januszewicz, Andrzej
    Witkowski, Adam
    Ruilope, Luis M.
    Whitbourn, Robert
    Bruck, Heike
    Downes, Mark
    Luescher, Thomas F.
    Jardine, Alan G.
    Webster, Mark W.
    Zeller, Thomas
    Sadowski, Jerzy
    Bartus, Krzysztof
    Straley, Craig A.
    Barman, Neil C.
    Lee, David P.
    Witteles, Ronald M.
    Bhalla, Vivek
    Massaro, Joseph M.
    [J]. LANCET, 2010, 376 (9756): : 1903 - 1909
  • [5] One year pooled outcomes following renal sympathetic denervation in patients with resistant hypertension: From the Symplicity HTN-2 trial
    Boehm, M.
    Schlaich, M. P.
    Krum, H.
    Schmieder, R. E.
    Sobotka, P.
    Esler, M. D.
    [J]. EUROPEAN HEART JOURNAL, 2012, 33 : 770 - 770
  • [6] Symplicity HTN-2: International, Multicenter, Prospective, Randomized, Controlled Trial of Endovascular Selective Renal Sympathetic Denervation for the Treatment of Hypertension
    Esler, Murray
    [J]. CIRCULATION, 2010, 122 (21) : 2220 - 2220
  • [7] RENAL SYMPATHETIC DENERVATION FOR TREATMENT OF DRUG-RESISTANT HYPERTENSION IN AN ASIAN POPULATION: RESULTS FROM THE GLOBAL SYMPLICITY REGISTRY IN SOUTH KOREA (GSR KOREA) AND COMPARISON TO SYMPLICITY HTN-2
    Kim, Byeong-Keuk
    Boehm, Michael
    Mahfoud, Felix
    Mancia, Giuseppe
    Park, Sungha
    Hong, Myeong-Ki
    Kim, Hyo-Soo
    Park, Seung-Jung
    Park, Chang Gyu
    Seung, Ki Bae
    Gwon, Hyeon-Cheol
    Choi, Dong-Ju
    Ahn, Tae Hoon
    Kim, Chong Jin
    Kwon, Hyuck Moon
    Esler, Murray
    Jang, Yangsoo
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (10) : A1521 - A1521
  • [8] Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial
    Esler, Murray D.
    Boehm, Michael
    Sievert, Horst
    Rump, Christian L.
    Schmieder, Roland E.
    Krum, Henry
    Mahfoud, Felix
    Schlaich, Markus P.
    [J]. EUROPEAN HEART JOURNAL, 2014, 35 (26) : 1752 - 1759
  • [9] Catheter-based renal sympathetic denervation in patients with resistant hypertension: 18 month follow-up of the Symplicity HTN-2 trial
    Esler, M. D.
    Krum, H.
    Schlaich, M. P.
    Schmieder, R. E.
    Boehm, M.
    Sobotka, P.
    [J]. EUROPEAN HEART JOURNAL, 2012, 33 : 181 - 181
  • [10] Resistant Hypertension and Renal Denervation. Considerations on the Results of the Symplicity HTN-3 Trial
    Ruilope, Luis M.
    Arribas, Fernando
    [J]. REVISTA ESPANOLA DE CARDIOLOGIA, 2014, 67 (11): : 881 - 882